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1. Introduction
Helicobacter pylori (H. pylori) is an universally distributed bacterium that affects more than half
of the world population and is considered an important public health problem. Although
colonization with H. pylori is not actually a disease, it is a condition that affects the relative risk
of developing various clinical disorders of the upper gastrointestinal tract, as chronic gastritis,
peptic ulcer disease, mucosa-associated lymphoid tissue (MALT lymphoma) and gastric
adenocarcinoma, and, possibly, extradigestive diseases.
Colonization with H. pylori virtually leads to infiltration of the gastric mucosa in both antrum
and corpus with neutrophilic and mononuclear cells. Gastritis can be classified as an acute or
chronic gastritis and it can involve all parts of the stomach or just the fundus, corpus or antrum.
The chronic active gastritis is the primary condition related to H. pylori colonization, and other
H. pylori-associated disorders, in particular, resulting from this chronic inflammatory process,
as atrophic gastritis, causing an elevated risk of gastric cancer. Considering this association,
in 1994 the bacterium was classified as a group I carcinogen by the International Agency for
Research on Cancer, World Health Organization.
Molecular techniques have revealed that H. pylori possesses a remarkable degree of genetic
diversity, which could be responsible for its adaptation in the host stomach and for its
pathological characteristics, in addition to the clinical outcome of the infection, although this
aspect remains unclear.
In Brazil, it is estimated that only about 10 to 15% of the gastric cancer cases are diagnosed at
an early stage, aspect that directly impact the prognosis of the disease, which presents low
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survival rates. Unlike patients with advanced gastric cancer, that ones diagnosed at the early
stage of the disease present an excellent prognostic, in which a five-year survival rate is more
than 90%.
Many early gastric cancers are believed to go through a life cycle consisting of ulcerations,
followed by healing, then reulceration, and some tumors remain at this early stage for years
even without treatment. Nevertheless, some of these tumors rapidly advanced, perhaps one
of the principal questions concerning the gastric carcinogenesis.
Consequently, some questions can be considered about it. Is the H. pylori presence important
for the evolution of the early lesions in advanced ones? To what extent H. pylori eradication
could prevent the progression of lesions from one to another stage? Are the genetic charac‐
teristics of H. pylori strain that is colonizing the patient with early gastric cancer important for
the progression of the disease in a faster or in a slower way?
The principal aim of our book chapter is to identify the genetic characteristics of H. pylori
strains in Brazilian patients diagnosed with early distal type intestinal gastric adenocarcino‐
ma,  trying  to  determine  the  genotypic  pattern  of  bacterium in  our  population  through
molecular techniques. Besides, other aim of our study is to discuss the principal aspects of
the H. pylori infection and then correlate them with the development of the precancerous
lesions and the development of the early gastric cancer properly, trying to understand to
what extent the microorganism eradication treatment could be important to preventing the
disease progression.
2. Helicobacter pylori
2.1. General characteristics
Helicobacter pylori (H. pylori) is a spiral-shaped Gram-negative flagellate bacterium that
colonizes the human stomach and can establish a long-term infection of the gastric mucosa [1].
In gastric biopsy specimens, H. pylori organisms are 2.5 to 5.0 μm long and 0.5 to 1.0 μm wide,
with four to six unipolar sheated flagella, which are essential for bacterial motility. When
cultured on solid medium, the bacteria assume a rod-like shape and spiral shapes are infre‐
quent or absent [2]; after prolonged culture on solid or liquid medium, coccoid forms, that are
metabolically active, tipically predominate [3].
Gastric colonization with H. pylori affects at least half the world´s population, and, while the
infection is on a fast decline in most of the western countries, mainly due to the success of
therapeutic regimens and improved personal and community hygiene that prevents re-
infection, the situation is exactly opposite in many of the developing countries due to failure
of treatment and emergence of drug resistance [4,5]. Most studies suggest that males and
females are infected at approximately the same rates [6] and, probably, the infection occurs in
the childhood. In developed countries, persons of higher socioeconomic status have lower
infection rates, although among certain ethnic minorities, high rates persist despite economic
advancement [7].
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The routes of transmission of H. pylori still remain unclear. Person-to-person transmission and
intrafamilial spread seem to be the main route, based on the intrafamilial clustering observed
in some studies [8,9]. Children are often infected by a strain which a genetic fingerprint
identical to that of their parents, and they maintain this genotype even after moving to a
different environment [10]. Animals harbor organisms that resemble H. pylori, but with the
exception of nonhuman primates [11] and, under particular circumstances, perhaps cats [12]
and houseflies (Musca domestica) [13], none harbor H. pylori. In the same way, food-borne
transmission has not been substantiated [14]. Nevertheless, the waterborne infection remains
possible [15,16].
H. pylori remains one of the most common worldwide human infections and its isolation by
Marshall and Warren (1984) [17] has markedly improved our understanding about the nature
of chronic gastritis and other important upper gastrointestinal disorders, such as peptic ulcer
disease, mucosa-associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma
[18]. In 1994, the bacterium was classified as a group I carcinogen by the International Agency
for Research on Cancer and is regarded as a primary factor for gastric cancer development [19].
For their revolutionary discovery, Marshall and Warren received the Nobel Prize in Physiology
or Medicine in 2005.
In addition, in the last years, H. pylori infection has also been associated with some extradi‐
gestive diseases, such as iron-deficiency anemia [20], idiopathic thrombocytopenic purpura
[21,22], cardiovascular diseases [23,24], hepatobiliary diseases [25,26], and diabetes mellitus
[27], among others.
2.2. Virulence factors of H. Pylori
H. pylori populations are highly diverse and constantly change their genome, which can be an
important factor in its adaptation to the host stomach and also for the clinical outcome of the
infection. The changes in its genome occur mainly due to point mutations, substitutions,
insertions, and/or deletions of their genome. Moreover, mixed infections are frequent and lead
to exchange of DNA fragments between different H. pylori strains in a single host [28,29].
Experience with other bacterial pathogens suggests that H. pylori-specific factors may exist that
influence the microorganism pathogenicity, and, these factors, together with the host genetic
characteristics and the external environment, can contribute to the clinical outcome of the
infection. Among the most studied virulence factors of H. pylori are the urease gene, the
vacuolating cytotoxin gene (vacA), the cytotoxin associated gene-Pathogenicity Island
(cagPAI) and the duodenal ulcer promoting gene (dupA).
Urease is  an important  enzyme which is  produced by H. pylori  to  counteract  the acidic
environment of the stomach. Urease causes damage to the epithelium through the produc‐
tion of ammonia, that, in conjunction with neutrophil metabolites, forms carcinogenic agents
that  might  participate  in  the  development  of  gastric  malignances  [30,31].  Ammonia  is
capable to cause different cell alterations, including swelling of intracellular acidic compart‐
ments, alterations of vesicular membrane transport, repression of protein synthesis and ATP
production, and cell-cycle arrest [32]. Urease might also help to the recruitment of neutro‐
phils and monocytes in the mucosa and to the production of proinflammatory cytokines
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[33]. It has been demonstrated that this enzyme plays and important hole in the H. pylori
colonization,  being observed that  urease-defective bacteria mutants are not  able to colo‐
nize the gastric environment [32].
VacA is a cytotoxin secreted from H. pylori as a large 140kd polypeptide and latter trimmed
at both ends to finally deliver it in an active form to host cells, where it exerts its activity
[34]. The gene encoding VacA is present in all H. pylori strains and displays allelic diversity
in three main regions: s (signal), i (intermediate) and m (middle); consequently, the activity
of the toxin varies between strains [35]. Different combinations of two major alleles of each
region (s1, s2, i1, i2, m1, m2) may exist, which results in VacA toxins with distinct capability
of inducing vacuolating in epithelial  cells  [36].  VacA induces multiple cellular activities,
including the alteration in the endosomal maturation which consequently leads to vacuolat‐
ing  of  epithelial  cells,  the  induction  of  membrane-channel  formation,  the  cytochrome  c
releasing  from  mitochondria  and  the  binding  to  cell-membrane  receptors  activating  a
proinflammatory response [35].
The cagPAI is a 40kb region of chromosomal DNA encoding approximately 31 genes that forms
a type IV secretion system that forms a pilus that delivers CagA, an oncoprotein, into the
cytosol of gastric epithelial cells through a rigid needle structure covered by CagY, a VirB10-
homologous protein and CagT, a VirB7-homologous protein, at the base [37,38]. cagA is a
polymorphic gene that presents different numbers of repeat sequences located in its 3´region
and each repeat region of the CagA protein contains Glu-Pro-IIe-Tyr-Ala (EPIYA) motifs,
including a tyrosine phosphorylation site [39]. Upon delivery into host cells, CagA undergoes
Src-dependent tyrosine phosphorylation and activates an eukaryotic phosphatase (SHP-2),
leading to dephosphorylation of host cell proteins and cellular morphologic changes [40].
CagA has also been shown to dysregulate β-catenin signaling [41] and apical-junctional
complexes [42], events that have been linked to increased cell motility and oncogenic trans‐
formation in a variety of models [43]. In addition, some studies have been reported that the
cagPAI appears to be involved in the induction of gastric interleukin-8 (IL-8) production, a
potent neutrophil-activating chemokine [44]. Consequently, the presence of the cagA gene has
been associated with higher grades of inflammation, which may lead to the development of
the most severe gastrointestinal diseases, such as peptic ulcer disease and gastric cancer [45-48].
H. pylori duodenal ulcer promoting gene (dupA), located in the plasticity region of bacterium
genome, has been initially described as a risk marker for duodenal ulcer development and a
protective factor against gastric cancer [49]. It was the first putative specific marker whose
association was described using strains obtained from in both Asian (Japan and Korea) and
Western (Colombia) regions and it is though to be a virB4 homologue [49, 50]. dupA gene
encompasses two continuous sequences, jhp0917 and jhp0918, as described in strain J99. The
jhp0917 gene encodes a protein of 475 amino acids, but lacks a region homologous to the C-
terminus of virB4, while jhp0918 gene encodes a product of 140 amino acids that is homologous
to the missing virB4 region [51]. Since its discovery, dupA gene has been studied by various
authors, and the results of their researches suggest that, in some places, dupA gene is not
associated with an specific disease [52], or it is suggested that it can be associated with gastric
cancer development [53-55], or it is directly associated with the development of duodenal ulcer
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disease [50,56]. Considering all these results, it is suggested that there must be diversity in gene
content that can contribute to bacterial adaptation to genetically different ethnic groups that
make up de human population [57].
3. Gastric cancer
3.1. Epidemiology
Cancer is a worldwide full-scale problem as it will affect one in three men and one in four
women during their lifetime [58]. Nowadays, this disease represents one in eight deaths
around the world. The global cancer rate has doubled in the last 30 years of the 20th century,
and will almost triple by 2030, a year in which it is foreseen that 20.3 million people will be
diagnosed cancer and 13.2 million will die as a result of this disease [59].
World Health Organization estimates that 43% of cancer deaths are due tobacco, diet and
infection. One-fifth of cancers worldwide are due to chronic infections, mainly from hepatitis
viruses (liver), papillomaviruses (cervix), H. pylori (stomach), schistosomes (bladder), the liver
fluke (bile duct), and human immunodeficiency virus (Kaposi sarcoma and lymphoma) [60].
Gastric cancer continues to be a major global health problem [61] and, despite the decreasing
incidence and mortality rates observed worldwide over the last 50 years, it still ranks as a
leading cause of cancer-related deaths in many parts of the world [62]. As symptoms are often
absent or nonspecific in patients with the early stages of the disease, gastric cancer is usually
diagnosed in an advanced stage, when curative options are limited. With exceptions in
countries that have developed screening programs for early diagnoses, as example Japan, most
patients reach treatment with cancers already in advanced stages [63]. Consequently, gastric
cancer carries a poor prognosis, with an overall five-year survival rate of less than 20% [64].
Besides, one study assessed the survival of gastric cancer in population-based registries
obtained in cities from four continents and concluded that the large differences observed
among these areas were exclusively due to the different types of stomach cancer, highlighting
the importance of the stage of the disease as an indicator of the effect of delayed diagnosis on
the prognosis of these patients [65].
In Brazil, in 2005, the highest incidence rates, adjusted by age, were found in São Paulo (male,
38,8/100.000; female, 15,0/100.000) and the Federal District (male, 32,7/100.000; female
14,7/100.000) [66]. The National Institute of Cancer in Brazil estimates that, in 2014, there will
occur 580.000 new cases of cancer. The most frequent cancers in Brazilian population will be
non-melanoma skin (182.000), prostate (69.000), breast (57.000), colon and rectum (33.000), lung
(27.000) and stomach (20.000). Considering Brazilian regions and gender, gastric cancer will
be the fourth most common cancer in Brazil. In male gender, it is the second most common
tumour in the North (11/100.000 cases) and Northeast (10/100.000 cases) regions; it is the fourth
most common tumour in the Midwest (11/100.000 cases) and in the South (16/100.000) regions
and the fifth most common in the Southeast region (15/100.000 cases). Concerning the female
gender, gastric cancer is the fifth most common cancer in Brazil, the third most frequent in the
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North region (6/100.000 cases), and the fifth most frequent in the Northeast (6/100.000 cases)
and Southeast (8/100.000 cases) regions [67].
The chances of surviving the onset of some common cancers depend largely on how early they
are detected and how well they are treated. Early detection is based on the observation that
treatment is more effective when cancer is detected early. It includes awareness of early signs
and symptoms of cancer and screening, which is the mass testing of people who appear to be
healthy. In many developing countries, where these are not feasible, several other low
technology approaches are being studied and look promising. The success of public health
programmes in detecting cancer early depends on the allocation of resources, availability of
qualified specialists and access to follow-up treatment [60].
3.2. Classification of gastric cancer
The vast majority of gastric cancers are adenocarcinomas. Two histologically distinct variants
of gastric adenocarcinoma have been described, each with different pathophysiological
features: the diffuse type and the intestinal type [68], which corresponds, respectively, to the
undifferentiated or poorly-differentiated type and to the well-differentiated type, in the
Japanese classification [69].
Diffuse type gastric adenocarcinoma is often associated with familial distribution and more
commonly affects younger people. It consists of individually infiltrating neoplastic cells that
do not form glandular structures and arises closer to the advancing border of inflammation
but without any identifiable histological precursor lesion [62,70,71].
Gastric adenocarcinoma of the intestinal type is preceded by a prolonged precancerous
process. In 1975, Correa and colleagues proposed a model of gastric carcinogenesis, postulating
that the intestinal type of gastric cancer was the end result of progressive changes in the gastric
mucosa, starting with chronic gastritis, followed by multifocal atrophic gastritis and intestinal
metaplasia [72]. This model was updated in 1988 and 1992 [73,74] and the following steps were
recognized: normal gastric mucosa → superficial gastritis (later renamed non-atrophic
gastritis) → multifocal atrophic gastritis without intestinal metaplasia → intestinal metaplasia
of the complete (small intestine) type → intestinal metaplasia of the incomplete (colonic) type
→ low-grade dysplasia (low-grade noninvasive dysplasia) → high-grade dysplasia (high-
grade noninvasive dysplasia) → invasive adenocarcinoma [75]. These lesions are well-
characterized histopathologically and represent a continuum of changes depicting multiple
events that increase in intensity and extension with time [76].
Both diffuse and intestinal types are associated with H. pylori infection, which plays an
initiating role in the pathogenesis of gastric cancer by changing many important factors,
including antioxidant agents, reactive oxygen metabolites, and the balance between epithelial
cell proliferation and apoptosis [77]. H. pylori infection induces cell apoptosis, stimulates cell
proliferation in the gastric epithelium, and causes alterations or mutations of apoptosis/
proliferation-related genes [78].
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3.3. Helicobacter pylori and gastric cancer — The precancerous cascade
Exposure of gastric epithelial cells to H. pylori results in an inflammatory reaction with the
production of reactive oxygen species and nitric oxide that, in turn, deaminates DNA causing
mutations [62]. The complex interplay among H. pylori strain, inflammation and host charac‐
teristics, besides the external environment, may directly promote diffuse type gastric cancer
or induce the cascade of morphological events that leads to intestinal type gastric cancer.
Specifically regarding to intestinal type gastric adenocarcinoma, evidence that H. pylori
increases the risk of gastric cancer development via the sequence of atrophy and metaplasia
originates from various studies, in which it was shown that H. pylori positive subjects develop
these conditions more often than do uninfected controls [79]. Consequently, since H. pylori
isolation, many investigators have emphasized its role in gastric carcinogenesis [80,81].
Epidemiological studies have determined that the attributable risk for gastric cancer conferred
by H. pylori is approximately 75% [82]. Besides, in respect to localization in the stomach,
premalignant lesions are most frequently localized in the antrum in the transitional zone
between the antrum and corpus [83].
As explained before, Correa and colleagues (1975) proposed a model of gastric carcinogenesis,
considering that the intestinal type gastric cancer probably is the result of histological contin‐
uum changes that occur especially due to H. pylori infection: chronic active nonatrophic
gastritis, multifocal atrophic gastritis, intestinal metaplasia, dysplasia, and, finally, invasive
adenocarcinoma. Consequently, the principal characteristics of each one of these stages are
report below.
3.3.1. Chronic active non-atrophic gastritis
Gastritis is characterized by increased infiltration of the lamina propria with mononuclear
leukocytes (chronic inflammation) and polymorphonuclear neutrophils (acute inflammation).
Additionally, scattered eosinophils and mast cells can be observed. The gastritis is called
“active” when polymorphonuclear neutrophils are found, representing acute inflammation.
This phase of the precancerous process does not show loss of glands (atrophy) and is called
“nonatrophic gastritis” in the updated Sydney classification of gastritis, adopted by most
pathologists (Figure 1) [84].
The most frequent cause of gastritis is H. pylori infection and the severity of inflammation may
vary according to the infected H. pylori strain [75].
3.3.2. Multifocal atrophic gastritis
Loss of normal glandular tissue is the first specific recognizable step in the precancerous
cascade. Usually it is the result of a prolonged inflammatory process and tends to be multifocal,
giving rise to the so-called multifocal atrophic gastritis (Figure 2). The foci of atrophy are
present in the mucosa of gastric antrum and body, and their extension progresses with time
[75]. More virulent bacterial strains and a permissive host immune response are strongly
associated with atrophy and progression to severe disease [84].
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(Copyright © Center of Diagnosis of Digestive Diseases, State University of Campinas, SP, Brazil. All rights reserved)
Figure 2. Atrophic gastritis
3.3.3. Intestinal metaplasia
At this stage of the gastric precancerous process, the original glands and the foveolar epithe‐
lium are replaced by cells with intestinal phenotype [84]. Intestinal metaplasia (Figure 3) is
considered to be an advanced stage of atrophy because the metaplastic glands replace the
original glands and chronologically the metaplastic glands appear after the gastric glands are
lost. Intestinal metaplasia has been classified on the basis of morphology and enzyme histo‐
chemistry in two main types: the small intestine or complete type, and the colonic or incom‐
plete type [75].
(Copyright © Center of Diagnosis of Digestive Diseases, State University of Campinas, SP, Brazil. All rights reserved)
Figure 1. Chronic gastritis
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Up to  this  point  in  the  cascade,  the  epithelium in  the  atrophic  and metaplastic  lesions
remains  well  differentiated,  with  normal  nuclear-cytoplasmic  ratio,  normal  nuclear
morphology, and normal tissue architecture. The dynamics of the precancerous process to
this point shows a gradual phenotypic transformation from normal epithelium to metaplas‐
tic  cells  with  small  intestinal  morphology and then to  cells  resembling  colonic  mucosa,
additionally expressing gastric and colonic mucins. This process usually takes decades and
is  progressive,  supporting  the  notion  that  although  environmental  alterations  (bacterial
factors and cytokine environment, loss of cell signaling) may have initially driven differen‐
tiation decisions, with time, permanent changes in the stem cell compartment have occurred.
In some patients with incomplete metaplasia, a mild degree of nuclear atypia and architec‐
tural distortion is observed, leading some investigators to consider incomplete metaplasia
as a mild form of dysplasia [84,85].
(Copyright © www.gastrolab.net/pawelcom.htm. All rights reserved)
Figure 3. Intestinal metaplasia (antrum)
3.3.4. Dysplasia
Also called intraepithelial neoplasia or noninvasive neoplasia, dysplasia is characterized by a
neoplastic phenotype, both in terms of cell morphology and architectural organization [75].
The nuclei of the dysplastic epithelium are enlarged, hyperchromatic, irregular in shape, and
devoid of polarity [84]. The Padova classification is focused on gastric dysplasia and was
developed by an international group of experienced gastrointestinal pathologists and recog‐
nizes five categories of lesions, utilizing mostly western nomenclature and grouping them
numerically following the prevailing Japanese system: 1. negative for dysplasia; 2. indefinite
for dysplasia; 3. noninvasive neoplasia (sub-classified in low grade or high grade); 4. suspicious
for invasive carcinoma; and 5. invasive carcinoma [86].
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The management of low-grade dysplasia is not well defined and there is a recommendation
of annual endoscopic monitoring with rebiopsy [87]. Nevertheless, patients with high-grade
dysplasia confirmed at least two gastrointestinal pathologists should undergo surgical or
endoscopic resection because of the high probability of coexisting or metachronous invasive
carcinoma [88].
3.3.5. Invasive adenocarcinoma
Invasive adenocarcinoma is the next stage in the cascade and requires the penetration of
neoplastic cells into the surrounding stroma (Figure 4). Recent evidence suggests that this step
demands that neoplastic cells acquire the capability of degrading the stromal matrix sur‐
rounding the neoplastic cells [75.
(Copyright © Center of Diagnosis of Digestive Diseases, State University of Campinas, SP, Brazil. All rights reserved)
Figure 4. Gastric adenocarcinoma
3.4. Early and advanced lesions
Follow-up of patients with precursor lesions in populations at high gastric cancer risk has
thrown light on the dynamics of the process. The progression of the precursor lesions described
before follows a pattern of steady state, with episodes of progression to more advanced lesions
and episodes of regression to less advanced lesions.
Unlike patients with advanced gastric cancer, patients diagnosed in an early stage of the
disease present an excellent prognostic, in which a five-year survival rate is more than 90%.
Early gastric cancer lesions are defined as the adenocarcinoma that is confined to the mucosa
or submucosa, irrespective of lymphonode invasion (Figure 5). Many early gastric cancers are
believed to go through a life cycle consisting of ulcerations, followed by healing, then reul‐
ceration, and some lesions remain at this early stage for years even without treatment [89].
Nevertheless, some early tumours rapidly became advanced and it is one of the principal
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questions concerning the gastric carcinogenesis. Are H. pylori virulence factors important to
influence these alterations? To what extent H. pylori eradication treatment would be important
to prevent the continued progression of the disease? To what extent H. pylori eradication in
the early stage of cancer would be important to prevent the appearance of new lesions?
(Copyright © Center of Diagnosis of Digestive Diseases, State University of Campinas, SP, Brazil. All rights reserved)
Figure 5. Early gastric adenocarcinoma
Considering these important questions, our chapter is divided into two sections: 1. the
identification of the principal genetic characteristics of H. pylori strains in Brazilian patients
with early distal type intestinal gastric adenocarcinoma, in order to determine the genotypic
pattern of bacterium in our population through molecular techniques; 2. the discussion of the
principal studies concerning H. pylori eradication and its importance to prevent the progression
of precancerous lesions and the importance of H. pylori eradication in the early gastric cancer
to prevent the development of new cancerous lesions.
4. Materials and methods
4.1. Determination of principal genotypes of H. Pylori in Brazilian patients with early gastric
adenocarcinoma
4.1.1. Clinical samples
Clinical isolates of H. pylori analyzed in this study were obtained from the Laboratory of
Pathology of the Center of Diagnosis of Digestive Diseases, Faculty of Medical Sciences, State
University of Campinas (Campinas, São Paulo, Brazil). Third one paraffin wax-embedded
specimens of gastric tissue were analyzed from a total of 31 patients with early distal type
intestinal gastric adenocarcinoma. All the gastric tissue samples were obtained from endo‐
scopic biopsy and were positive for H. pylori by histological analysis. Samples from gastric
tissue obtained from endoscopic biopsy of patients with chronic gastritis and peptic ulcer
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disease and positive for H. pylori were used as positive controls for all the reactions carried out
in this study. The study was approved by the Ethics Committee of the Faculty of Medical
Sciences, State University of Campinas.
4.1.2. Methods
Paraffin wax-embedded tissue DNA extraction was carried out with xylene and ethanol
washes for paraffin removal; successive steps using proteinase K, phenol, chloroform, and
isoamyl alcohol were carried out in order to isolate and purify the DNA [90]. Quantification
of the obtained product and polymerase chain reaction (PCR) for human betaglobin gene [91]
were carried out to guarantee the quality of all the results.
After DNA extraction, PCR for ureaseC [92], vacA (s and m) [93,94,95], cagA [96], cagT [97]
and dupA (jhp0917 and jhp0918) [49] genes were performed. Primers pairs for all the genes as
well as the length of the fragments are described in Table 1. PCR for ureaseC gene was carried
out to confirm the positivity for H. pylori in all the samples.
After amplification, each PCR product was analyzed by eletrophoresis on a 2% agarose gel
stained with ethidium bromide with a 0.5 X tris-acetate-EDTA buffer. A 100-bp ladder was
used as standard.
Gene Strand Primer sequence (5´ - 3´) Length (bp)
betaglobin +-
ACAAACTGTGTTCACTAGC
CAACTTCATCCACGTTTCACC 110
ureaseC +-
AAGCTTTAGGGGTGTTAGGGGTTT
AAGCTTACTTTCTAACACTAACGC 294
vacA (s1/s2) +-
ATGGAAATACAACAAACACAC
CTGCTTGAATGCGCCAAAC
s1: 259
s2: 286
vacA m1 +-
GGTCAAAATGCGGTCATGG
CCATTGGTACCTGTAGAAAC 290
vacA m2 +-
ATGCTTTAATATCGTTGAGA
GAACATGTTTTAGTGAAAGC 198
cagA +-
GATAACAGGCAAGCTTTTGAGG
CTGCAAAAGATTGTTTGGCAGA 349
cagT +-
CCATGTTTATACGCCTGTGT
CATCACCACACCCTTTTGAT 301
dupA (jhp0917) +-
TGGTTTCTACTGACAGAGCGC
AACACGCTGACAGGACAATCTCCC 307
dupA (jhp0918) +-
CCTATATCGCTAACGCGCGCTC
AAGCTGAAGCGTTTGTAACG 276
Table 1. Sequence of synthetic oligonucleotide primers used to characterization of H. pylori strains
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Then, for each specific reaction, products obtained were classified in vacA s1m1, s2m1, s1m2
or s2m2; cagA positive or negative; cagT positive or negative; and dupA positive or negative.
dupA gene was considered positive when its two regions (jhp0917 and jhp0918) were positive
simultaneously.
After all amplifications, a table with absolute frequencies (n) and percentages (%) was made
in order to determine genotypes combinations.
4.2. Analysis of the principal manuscript references concerning the study of eradication
treatment of H. pylori in precancerous lesions and early gastric cancer
After determination of the principal genotype presented in Brazilian patients with early gastric
cancer, a review concerning the importance of eradication of H. pylori in precancerous lesions
and in early gastric adenocacinoma was done.
5. Results
5.1. Determination of principal genotypes of H. Pylori in Brazilian patients with early gastric
adenocarcinoma
PCR for ureaseC gene of H. pylori was positive for all 31 samples obtained from patients with
early distal type intestinal gastric adenocarcinoma. As regards to vacA gene region s, of 31
samples, 71.0% (22 cases) were s1 and 29.0% (9 cases) were s2. Related to the vacA region m,
all the samples were m1. Following this analysis, samples were classified in s1m1 or s2m1. So,
71.0% (22 cases) were s1m1 and 29.0% (9 cases) were s2m1.
Classification
UreaseC 31 (100.0%)
vacA s1
vacA s2
22 (71.0%)
9 (29.0%)
vacA m1
vacA m2
31 (100.0%)
0 (0.0%)
vacA s1m1
vacA s2m1
22 (71.0%)
9 (29.0%)
cagA positive
cagA negative
19 (61.3%)
12 (38.7%)
cagT positive
cagT negative
17 (54.8%)
14 (45.2%)
dupA (jhp0917/jhp0918) positive
dupA (jhp0917/jhp0918) negative
11 (35.5%)
20 (64.5%)
Total 31 (100.0%)
Table 2. Frequencies and percentages of the principal genes of H. pylori studied in samples of early gastric cancer
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As regards to gene cagA, 61.3% (19 cases) were cagA positive and, for cagT gene, 54.8% (17
cases) were positive. For dupA (jhp0917/jhp0918) gene, there were 35.5% (11 cases) of posi‐
tivity. All these results can be seen in Table 2.
Genotypes combinations where then analyzed and the most prevalent genotype for gastric
samples obtained from Brazilian patients with early distal type intestinal gastric adenocarci‐
noma was vacA s1m1, cagA positive, cagT positive and dupA negative (Table 3).
Genotype combinations:
vacA s/m cagA cagT dupA (jhp0917/jhp0918)
Early gastric cancer
s1m1 neg neg neg 4 (12.90)
s1m1 neg neg pos 1 (3.23)
s2m1 neg neg neg 1 (3.23)
s2m1 neg neg pos 0 (0.00)
s1m1 neg pos neg 2 (6.45)
s1m1 neg pos pos 1 (3.23)
s2m1 neg pos neg 2 (6.45)
s2m1 neg pos pos 1 (3.23)
s1m1 pos neg neg 3 (9.68)
s1m1 pos neg pos 2 (6.45)
s2m1 pos neg neg 2 (6.45)
s2m1 pos neg pos 1 (3.23)
s1m1 pos pos neg 5 (16.13)
s1m1 pos pos pos 4 (12.90)
s2m1 pos pos neg 2 (6.45)
s2m1 pos pos pos 0 (0.00)
Total 31
Table 3. Genotype combinations for early gastric adenocarcinoma samples
5.2. Analysis of the principal manuscript references concerning the study of eradication
treatment of H. pylori in precancerous lesions and early gastric cancer
Epidemiological studies have established a strong causal relationship between H. pylori
infection and gastric cancer. H. pylori eradication is therefore likely to be one of the most
promising approaches to gastric cancer prevention. Animal studies have shown that eradica‐
tion of H. pylori infection, especially at the early stage, is effective in preventing H. pylori-related
gastric carcinogenesis. However, the available data from human studies show that H. pylori
eradication does not completely prevent gastric cancer and that it might be useful in patients
without atrophic gastritis or intestinal metaplasia at baseline [77].
Considering these important issues, the present chapter book analized and discussed some
studies that assessed the possible relationship between the eradication of H. pylori infection
and the prevention of gastric cancer even if the precancerous cascade has started. Obviously,
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there should be a point which there is no return in this process and the presence of H. pylori
could not be more decisive to continue the progression of the precancerous lesions. With the
aim to analyze these topics, we discussed some important questions concerning H. pylori
infection, precancerous cascade and H. pylori eradication treatment, both in the precancerous
lesions (atrophic gastritis, metaplasia intestinal and dysplasia) and in the early gastric cancer
stage.
6. Discussion
Molecular techniques may be applied to the measurement of host or agent factors and of
exposures.  Molecular  techniques  help  to  stratify  and  to  refine  data  by  providing  more
sensitive  and  specific  measurements,  which  facilitate  epidemiologic  activities,  including
disease  surveillance,  outbreak  investigations,  identifying  transmission  patterns  and  risk
factors  among  apparently  disparate  cases,  characterizing  host-pathogen  interactions,
detecting uncultivatable organisms, providing clues for possible infectious causes of cancer
and other chronic diseases, and providing better understanding of disease pathogenesis at
the molecular level [98].
Our study determined the principal genotype of H. pylori strains in Brazilian patients with
early distal type intestinal gastric adenocarcinoma, which is vacA s1m1, cagA positive, cagT
positive and dupA negative. It provides to the scientific community important information
concerning the epidemiology of gastric cancer in Brazil, as regards to the infecting strains. This
principal H. pylori genotype was also the principal found in advanced gastric cancer samples,
but, when considering the cagA gene in an isolate evaluation, it was more incident in patients
with advanced gastric cancer [48].
Many factors, including a high-salt diet [99], genetic abnormality [100] and autoimmune
gastritis [101], among others, have been reported concerning gastric carcinogenesis; however,
it is clear that H. pylori infection is the most important gastric carcinogen [60, 102].
Currently recommended anti-H. pylori infection therapies achieve eradication rates of up to
90% [103]. Several studies have indicated that H. pylori screening and eradication is a cost-
effective strategy for the prevention of gastric cancer in middle-aged adults, even if the
treatment prevents only 20%-30% of H. pylori-associated cancers, and that the strategy is
particularly beneficial in high-risk populations and in the long term [77,104,105,106], although
the feasibility, safety and appropriated timing of this strategy for cancer prevention in the
general population remains to be determined [77].
Some studies focused on patients with gastric precancerous lesions such as gastric atrophy,
intestinal metaplasia and dysplasia and evaluated the effect of eradicating H. pylori on the
intermediate lesions in the carcinogenic cascade rather than using gastric cancer as the primary
end points [107].
Conflicting results have been reported on whether or not these precancerous lesions were
reversible following successful eradication of H. pylori infection.
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The investigation of Uemura et al. (2001) [108] is considered the first study providing some
evidence that H. pylori eradication has an impact in gastric cancer. In this study, none of the
253 treated patients developed cancer, whilst there were 36 gastric cancer cases among 993
untreated patients. However, it is of note that the mean duration of follow-up after eradication
was significantly shorter than the mean duration for patients who were not treated (4,8 vs. 8,5
years; p < 0.001). Therefore, the risk of gastric cancer development could have been understated
in the treated group [107].
In a randomized placebo controlled study in China, gastritis (acute and chronic) decreased in
both the antrum and the corpus at one year after H. pylori eradication and a slight regression
of intestinal metaplasia was observed [109]. With similar results, a follow-up study developed
by Zhou et al. (2003) [110] demonstrated that H. pylori eradication significantly reduced the
severity and activity of chronic gastritis. Besides, while the proportion of intestinal metaplasia
in the H. pylori positive group increased significantly, intestinal metaplasia in the antrum either
regressed or had no progression in the H. pylori negative group.
In Colombia, a randomized, controlled chemoprevention trial with patients with confirmed
multifocal nonmetaplastic atrophy and/or intestinal metaplasia demonstrated that, after H.
pylori eradication therapy and/or dietary supplementation with ascorbic acid or beta-carotene,
or their placebos, it was observed a significant increase in the rate of regression of the precursos
lesions [111].
Other follow-up studies also identified that H. pylori eradication in patients with intestinal
metaplasia could be important in the regression of the lesions [112-118]. In the same way, other
randomized studies identified that H. pylori eradication in intestinal metaplasia could be
important in the regression of this precancerous lesion [76,109-111,119,120]. Oppositely, other
trials, both follow-up and randomized control, had not identified regression of intestinal
metaplasia when H. pylori eradication was administrated [121-129].
Concerning to patients with gastric atrophy, the most part of the studies have identified that
this lesion presents a regression when H. pylori eradication occurs [76, 109, 111, 119, 120,
128-130]. In Japan, where there is a significant ability in diagnostic, with a detection of 94% of
early gastric cancers, one important multicenter randomized controlled trial by the Japan Gast
Study Group enrolled patients undergoing previous endoscopic therapy for gastric cancer and
demonstrated that eradication therapy significantly reduced the prevalence of secondary
gastric cancer in a 3-year follow-up period [131]. However, this study does not demonstrate
that eradication therapy can prevent newly developed gastric cancer even in secondary cancer,
because the follow-up period was too short.
As well as other authors mentioned before, Ito (2009) [132] considered that theoretically H.
pylori eradication therapy should be beneficial for cancer prevention. However, attention
should be drawn to the fact that the gastric cancer risk is not similar between noninfected and
eradicated people. Until now, many human studies have demonstrated that some patients
develop gastric cancer even if they have undergone successful eradication therapy [133].
Considering it, we can conclude that eradication therapy may have an effect on cancer
prevention if the therapy is administrated before a single cancer cell has transformed or before
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cancer tissue shows invasive growth. It is likely that eradication therapy has no effect if the
cancer has progressed to an advanced stage.
Wong et al. (2004) [134], with the aim to determine whether eradication of H. pylori infection
reduces the incidence of gastric cancer, carried out a randomized, placebo controlled trial with
1630 H. pylori infected patients in a high-risk region of China. Their results indicated that H.
pylori eradication can reduce the incidence of gastric cancer in patients without precancerous
lesions at entry. Besides, the eradication therapy had no statistically significant effect on the
incidence of gastric cancer in patients with precancerous lesions on presentation. It appears
that there is a point of no return for patients with precancerous lesions and a chemoprevention
strategy may work only in a subset of H. pylori infected subjects [135].
As regards to animal models, they are useful because they represent tractable systems that
permit insights into the effects of host, pathogen and environmental factors on gastric
carcinogenesis [136]. Nevertheless, the use of animals does not completely reflect H. pylori-
induced cancer in humans. Romero-Gallo et al. (2008) [137], using a population of gerbils that
received antibiotics for H. pylori treatment, demonstrated that the timing of intervention
influences the magnitude of suppression of pro-inflammatory cytokine expression, inflam‐
mation, pre-malignant, and neoplastic lesions. These findings have demonstrated that
treatment of H. pylori decreases the incidence and the severity of pro-inflammatory cytokine
expression, as well as premalignant and malignant lesions. However, the effectiveness of
eradication is dependent upon the timing of intervention [137].
A 5-year study in Japanese monkeys (Macaca fustata) demonstrated that H. pylori infection can
cause gastric atrophy, increased cell proliferation, and mutation of p53 in gastric epithelial cells
[138]. In other study, with Mongolian gerbils, it was demonstrated that the resulting patho‐
logical changes in gastric mucosa are similar to those in humans [139]. Some studies demon‐
strated that when the animals were infected with H. pylori together with a carcinogen (N-
methyl-N-nitrosourea or N-methyl-N-nitro-N-nitrosoguanidine), they developed gastric
cancer (both diffuse and intestinal types) that were at significantly higher frequencies than
animals receiving either H. pylori or the carcinogen alone [140-142]. Gastric cancer incidence
was reduced at 75 weeks to 6.7%, 27.3%, and 38.2% in Mongolian gerbils receiving eradication
treatment at early (15 weeks), middle (35 weeks) and late (55 weeks) stages, respectively. These
results suggest that eradication at an early stage might be effective in preventing carcinogen‐
esis. Other study demonstrated that application of antimicrobial therapy at 8 weeks postino‐
culation of bacterium attenuated inflammation, but did not completely prevent the
development of premalignant and malignant lesions, indicating that the H. pylori eradication
therapy is effective when administered at an early stage after infection [143]. Nevertheless, it
is important to remember that the carcinogenic potential of H. pylori is strain dependent and
some results of these studies could be caused by the use of an H. pylori strain that lacked
carcinogenic potential.
In the mouse model, both H. pylori infection and gastric atrophy increase the serum concen‐
tration of polypeptide hormone gastrin, a hormone that controls secretion of gastric acid by
the stomach´s parietal cells and hypergastrinemia is regarded to play a role in the development.
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The results obtained indicated that the timing of antimicrobial eradication therapy is very
important as early application can prevent the progression of gastric cancer [144].
Finally, for cancers detected early, endoscopic mucosal resection can conserve the noncancer‐
ous gastric mucosa, but it can not eliminate the recurrence of metachronous gastric cancer
[145]. Fukase et al. (2008) [131], in a randomized control trial, studied a group of patients
submitted to H. pylori eradication therapy following endoscopic resection of early gastric
cancer. These patients were monitored at different time intervals: at 3 years, metachronous
gastric cancer had developed in 9 of 225 patients in the eradication group compared with 24
of 250 patients in the control group, suggesting that prophylactic eradication of H. pylori in a
high-risk population can substantially reduce gastric cancer rates.
Briefly, the most part of the studies suggests that H. pylori eradication is able to induce
regression of precancerous lesions in most of the treated subjects, and particularly in those
with baseline, early and non-severe lesions. However, it also seems that a proportion of treated
subjects will still show progression of preneoplastic lesions. So, we can consider that they really
are other factors that contribute to the progression of these lesions. So, H. pylori eradication is
an effective strategy in reducing the risk of gastric cancer; however, it is not efficient enough
to eradicate gastric cancer. Prevention of the infection, H. pylori immunization, H. pylori
eradication in the youth, selection of the high-risk population, and alternative chemopreven‐
tive measures may be essential for optimal management of malignancy of the stomach.
7. Conclusions
All the available evidence suggests that H. pylori eradication might represent a primary chemo-
preventive strategy in a subset of subjects. However, H. pylori eradication in those patients
who have already developed advanced preneoplastic lesions does not prevent gastric cancer
development, and endoscopic follow-up should always be performed.
More research is needed to elucidate mechanisms underlying the H. pylori-induced gastric
carcinogenesis. As the infection usually depends on the characteristics of the infecting strain,
studies that determine the genotypes in gastric cancer, as we presented in our study, are
necessary. Besides, more trials concerning the interaction among the infecting strain, the host
characteristics and the external environment are also needed to explaining the complex gastric
carcinogenesis. An understanding of biochemical, genetic and epigenetic changes following
eradication therapy would be helpful to develop strategies to identify high-risk individuals,
thereby contributing to effective management in gastric cancer prevention.
Finally, it is important to gain more insight into the pathogenesis of H. pylori-induced gastric
adenocarcinoma, not only to develop more effective treatments for this cancer, but also because
it might serve as a paradigm for the role of chronic inflammation in the genesis of other
malignancies.
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